Kymera Therapeutics (KYMR) – Research Analysts’ Weekly Ratings Changes

Kymera Therapeutics (NASDAQ: KYMR) recently received a number of ratings updates from brokerages and research firms:

• 11/18/2024 – Kymera Therapeutics is now covered by analysts at Stephens. They set an “overweight” rating and a $65.00 price target on the stock.
• 11/6/2024 – Kymera Therapeutics had its price target raised by analysts at Morgan Stanley from $45.00 to $49.00. They now have an “equal weight” rating on the stock.
• 11/4/2024 – Kymera Therapeutics had its price target lowered by analysts at UBS Group AG from $80.00 to $74.00. They now have a “buy” rating on the stock.
• 11/1/2024 – Kymera Therapeutics had its price target raised by analysts at Guggenheim from $45.00 to $52.00. They now have a “buy” rating on the stock.
• 11/1/2024 – Kymera Therapeutics had its “buy” rating reaffirmed by analysts at Truist Financial Co.. They now have a $53.00 price target on the stock, down previously from $54.00.
• 9/27/2024 – Kymera Therapeutics had its price target raised by analysts at Oppenheimer Holdings Inc. from $52.00 to $56.00. They now have an “outperform” rating on the stock.

Kymera Therapeutics Stock Up 0.1 %

Shares of KYMR traded up $0.06 during trading hours on Thursday, reaching $44.11. 336,520 shares of the company traded hands, compared to its average volume of 586,818. The company’s fifty day moving average price is $46.99 and its two-hundred day moving average price is $41.83. The company has a market capitalization of $2.86 billion, a price-to-earnings ratio of -18.85 and a beta of 2.21. Kymera Therapeutics, Inc. has a 12 month low of $18.89 and a 12 month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. During the same period last year, the business earned ($0.90) earnings per share. The business’s revenue was down 20.9% on a year-over-year basis. On average, analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Transactions at Kymera Therapeutics

In related news, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. Insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Values First Advisors Inc. bought a new position in Kymera Therapeutics in the third quarter valued at about $61,000. Quarry LP bought a new stake in Kymera Therapeutics during the third quarter valued at approximately $95,000. Mirae Asset Global Investments Co. Ltd. raised its position in Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after acquiring an additional 504 shares during the period. Comerica Bank boosted its stake in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after acquiring an additional 400 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado purchased a new position in shares of Kymera Therapeutics during the 2nd quarter worth $139,000.

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.